Neil E. Kay

30.8k total citations · 2 hit papers
493 papers, 17.3k citations indexed

About

Neil E. Kay is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Neil E. Kay has authored 493 papers receiving a total of 17.3k indexed citations (citations by other indexed papers that have themselves been cited), including 411 papers in Genetics, 238 papers in Pathology and Forensic Medicine and 191 papers in Immunology. Recurrent topics in Neil E. Kay's work include Chronic Lymphocytic Leukemia Research (407 papers), Lymphoma Diagnosis and Treatment (221 papers) and Immunodeficiency and Autoimmune Disorders (128 papers). Neil E. Kay is often cited by papers focused on Chronic Lymphocytic Leukemia Research (407 papers), Lymphoma Diagnosis and Treatment (221 papers) and Immunodeficiency and Autoimmune Disorders (128 papers). Neil E. Kay collaborates with scholars based in United States, United Kingdom and Italy. Neil E. Kay's co-authors include Tait D. Shanafelt, Diane F. Jelinek, Timothy G. Call, Clive S. Zent, Susan L. Slager, Michael R. Grever, Nancy D. Bone, Cheson Bd, J M Bennett and Stephen J. O’Brien and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Neil E. Kay

473 papers receiving 16.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment

1996 1.5k citations Neil E. Kay et al. Blood profile →
ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

2004 659 citations Michael J. Keating, Neil E. Kay et al. profile →

Peers

Countries citing papers authored by Neil E. Kay

Since Specialization

Citations

This map shows the geographic impact of Neil E. Kay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil E. Kay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil E. Kay more than expected).

Fields of papers citing papers by Neil E. Kay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil E. Kay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil E. Kay. The network helps show where Neil E. Kay may publish in the future.

Co-authorship network of co-authors of Neil E. Kay

This figure shows the co-authorship network connecting the top 25 collaborators of Neil E. Kay. A scholar is included among the top collaborators of Neil E. Kay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil E. Kay. Neil E. Kay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia 2024 ·SHILAP Revista de lepidopterología ·(unknown), Qianqian Guo, Yuan Gao, Sutapa Sinha, Zhenqing Ye, Weiguo Han, Kari G. Rabe, (unknown), (unknown), Chuanhe Yu, Esteban Braggio, Sameer A. Parikh, Susan L. Slager, Neil E. Kay, Zhiquan Wang	0
2	Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations 2024 ·Cancers ·(unknown), (unknown), Daniel R. O’Brien, Erik Jessen, Cecília Bonolo de Campos, Nicholas Boddicker, (unknown), Cristine Allmer, Kari G. Rabe, James R. Cerhan, Sameer A. Parikh, Neil E. Kay, Huihuang Yan, Daniel L. Van Dyke, Susan L. Slager, Esteban Braggio	2
3	Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature 2024 ·Blood ·(unknown), Brian Giacopelli, Kari G. Rabe, (unknown), Yue-Zhong Wu, Huihuang Yan, Tait D. Shanafelt, Sameer A. Parikh, Wei Ding, Paul J. Hampel, (unknown), James R. Cerhan, Celine M. Vachon, Neil E. Kay, Curtis A. Hanson, Alexander S. Parker, Esteban Braggio, Susan L. Slager, Christopher C. Oakes	2
4	Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL) 2024 ·Blood Cancer Journal ·Aswin Sekar, (unknown), Sameer A. Parikh, Giulio Genovese, Dennis P. Robinson, Aaron D. Norman, Janet E. Olson, Kari G. Rabe, (unknown), Nicholas Boddicker, Paul J. Hampel, Neil E. Kay, James R. Cerhan, Esteban Braggio, Curtis A. Hanson, Celine M. Vachon, Tait D. Shanafelt, Benjamin L. Ebert, Susan L. Slager	3
5	Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection 2022 ·Leukemia & lymphoma ·(unknown), Neil E. Kay, Sameer A. Parikh, Kari G. Rabe, Timothy G. Call, José F. Leis, Wei Ding, Susan L. Slager, Jacob D. Soumerai, Lindsey E. Roeker, Anthony R. Mato, Andrew D. Zelenetz	2
6	Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis 2022 ·Leukemia ·Nicholas Boddicker, Sara J. Achenbach, Sameer A. Parikh, Geffen Kleinstern, Esteban Braggio, Aaron D. Norman, Kari G. Rabe, Celine M. Vachon, Connie Lesnick, Timothy G. Call, Janet E. Olson, James R. Cerhan, Neil E. Kay, Curtis A. Hanson, Tait D. Shanafelt, Susan L. Slager	3
7	Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19 2022 ·Blood Advances ·Juan G. Ripoll, (unknown), Justin E. Juskewitch, Raymund R. Razonable, Ravindra Ganesh, Ryan T. Hurt, Elitza S. Theel, James R. Stubbs, Jeffrey L. Winters, Sameer A. Parikh, Neil E. Kay, Michael J. Joyner, Jonathon W. Senefeld	12
8	Progression and survival of MBL: a screening study of 10 139 individuals 2022 ·Blood ·Susan L. Slager, Sameer A. Parikh, Sara J. Achenbach, Aaron D. Norman, Kari G. Rabe, Nicholas Boddicker, Janet E. Olson, Geffen Kleinstern, Connie Lesnick, Timothy G. Call, James R. Cerhan, Celine M. Vachon, Neil E. Kay, Esteban Braggio, Curtis A. Hanson, Tait D. Shanafelt	13
9	Aspirin and other nonsteroidal anti‐inflammatory drugs, statins and risk of non‐Hodgkin lymphoma 2021 ·International Journal of Cancer ·Mark Liebow, Melissa C. Larson, Carrie A. Thompson, Grzegorz S. Nowakowski, Timothy G. Call, William R. Macon, Neil E. Kay, Thomas M. Habermann, Susan L. Slager, James R. Cerhan	7
10	The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL 2021 ·Blood ·Sameer A. Parikh, Kari G. Rabe, Neil E. Kay, Timothy G. Call, Wei Ding, José F. Leis, Saad S. Kenderian, Eli Muchtar, Yucai Wang, Amber B. Koehler, Susan M. Schwager, Connie Lesnick, Geffen Kleinstern, Daniel Van Dyke, Curtis A. Hanson, Esteban Braggio, Susan L. Slager, Tait D. Shanafelt	23
11	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice 2020 ·Cancer Medicine ·Sameer A. Parikh, Sara J. Achenbach, Timothy G. Call, Kari G. Rabe, Wei Ding, José F. Leis, Saad S. Kenderian, Asher Chanan‐Khan, Amber B. Koehler, Susan M. Schwager, Eli Muchtar, Amie Fonder, Kristen McCullough, (unknown), Matthew D. Smith, Susan L. Slager, Neil E. Kay, Heidi D. Finnes, Tait D. Shanafelt	39
12	Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry 2017 ·Clinical Lymphoma Myeloma & Leukemia ·Anthony R. Mato, Chadi Nabhan, Neil E. Kay, Nicole Lamanna, Thomas J. Kipps, David L. Grinblatt, Christopher R. Flowers, Charles M. Farber, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, (unknown), Kristen Sullivan, E. Dawn Flick, Jeff P. Sharman	24
13	Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs 2015 ·Molecular Cancer Therapeutics ·Shuntaro Tsukamoto, Yuhui Huang, Motofumi Kumazoe, Connie Lesnick, Shuhei Yamada, Naoki Ueda, Takashi Suzuki, Shuya Yamashita, Yoon Hee Kim, Yoshinori Fujimura, Daisuke Miura, Neil E. Kay, Tait D. Shanafelt, Hirofumi Tachibana	35
14	Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors 2015 ·Clinical Cancer Research ·Sutapa Sinha, Justin C. Boysen, (unknown), Charla Secreto, Steven L. Warner, David J. Bearss, Connie Lesnick, Tait D. Shanafelt, Neil E. Kay, Asish K. Ghosh	59
15	Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes 2013 ·Cancer Epidemiology Biomarkers & Prevention ·Susan L. Slager, Sara J. Achenbach, Yan W. Asmann, Nicola J. Camp, Kari G. Rabe, Lynn R. Goldin, Timothy G. Call, Tait D. Shanafelt, Neil E. Kay, Julie M. Cunningham, Alice H. Wang, J. Brice Weinberg, Aaron D. Norman, Brian K. Link, José F. Leis, Celine M. Vachon, Mark C. Lanasa, Neil E. Caporaso, Anne J. Novak, James R. Cerhan	12
16	Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma 2010 ·Cancer Epidemiology Biomarkers & Prevention ·Jennifer L. Kelly, Anne J. Novak, Zachary S. Fredericksen, Mark Liebow, Stephen M. Ansell, Ahmet Doǧan, Alice H. Wang, Thomas E. Witzig, Timothy G. Call, Neil E. Kay, Thomas M. Habermann, Susan L. Slager, James R. Cerhan	34
17	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia 2010 ·Blood ·Tait D. Shanafelt, Matthew T. Drake, Matthew J. Maurer, Cristine Allmer, Kari G. Rabe, Susan L. Slager, George J. Weiner, Timothy G. Call, Brian K. Link, Clive S. Zent, Neil E. Kay, Curtis A. Hanson, Thomas E. Witzig, James R. Cerhan	104
18	De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience 2009 ·Blood ·Constantine S. Tam, Tait D. Shanafelt, William G. Wierda, Lynne V. Abruzzo, Daniel L. Van Dyke, Susan O’Brien, Alessandra Ferrajoli, Susan Lerner, Alice Lynn, Neil E. Kay, Michael J. Keating	114
19	Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression 2009 ·Blood ·Asish K. Ghosh, Charla Secreto, Traci R. Knox, Wei Ding, Debabrata Mukhopadhyay, Neil E. Kay	189
20	Direct antiglobulin "Coombs'" test. Incidence of positive findings in normal population: retrospective study. 1978 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Neil E. Kay, Kim Anderson	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact